Miniatura

Fitxers

249818.pdf (685.21 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-03-14

Llicència de publicació

cc-by-nc (c) Ortiz-Gracia, A. et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219063

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1136/archdischild-2021-322996

Resum

Background: Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Similar anti-HIV drugs have been associated with mitochondrial toxicity but this has never been explored in CMV. Objective: To determine the potential mitochondrial toxicity profile at the genetic, functional and biogenesis level in peripheral blood mononuclear cells from a cohort of newborns and infants with symptomatic congenital CMV infection (treated with valganciclovir, untreated and uninfected controls). Design: Longitudinal, observational and controlled study. Setting and patients: Subjects were recruited at the tertiary referral Hospital Sant Joan de Déu and experiments were conducted at IDIBAPS-Hospital Clínic of Barcelona, Spain. CMV-infected newborns underwent comprehensive monthly clinical follow-up. Methods: Mitochondrial parameters, audiometry and neurological assessment were measured at baseline, 3-6 and 12 months after inclusion in the study. The Kruskal-Wallis test for k-independent samples and Friedman tests for repeated measurements were applied. Results: Complex IV, citrate synthase enzymatic activities and mtDNA remained preserved in congenital CMV-infected infants treated with valganciclovir compared with controls (p>0.05 in all cases). Conclusions: No evidence of mitochondrial toxicity was found in infants treated with valganciclovir for congenital CMV.

Matèries

Infants, Infeccions per citomegalovirus, Medicaments antivírics

Matèries (anglès)

Children, Cytomegalovirus infections, Antiviral agents

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ORTIZ RODRIGO, Alba, RÍOS, María, TOBÍAS, Ester, NOGUERA JULIAN, Antoni, GARCÍA GARCÍA, Francesc josep, CANTÓ SANTOS, Judith, VALLS-ROCA, Laura, GARRABOU TORNOS, Glòria, GRAU, Josep maria, CARDELLACH, Francesc, SÁNCHEZ, Emilia, MORÉN NÚÑEZ, Constanza, FORTUNY GUASCH, Claudia. Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir. _Archives of Disease in Childhood_. 2022. Vol. 107, núm. 7, pàgs. 686-691. [consulta: 20 de gener de 2026]. ISSN: 0003-9888. [Disponible a: https://hdl.handle.net/2445/219063]

Exportar metadades

JSON - METS

Compartir registre